Skip to content

Comparison of two treatments for chronic plaque psoriasis

The number of included studies counted by Review Manager (RevMan) is higher than these figures (190) because we entered each study reporting a placebo and an active comparison into the ‘Characteristics of included studies’ table as 2 studies. In trials comparing the two modes of maintenance therapy, slightly higher rates of infusion-related reactions have been observed among recipients of intermittent maintenance therapy 127,128. Compare the options. Treatment with narrow-band UVB phototherapy can be given three or two times a week.

Comparison of two treatments for chronic plaque psoriasis 2Psoriasis is a skin disorder that is characterized by scaly plaques, itching, and redness. Comparisons of drugs within each class was beyond the scope of this report. In patients with chronic plaque psoriasis, what is the comparative effectiveness of systemic biologic agents and systemic nonbiologic agents (between-class comparisons on an individual drug level) or phototherapy when evaluating intermediate (plaque BSA measurement, PASI, Patient s Assessment of Global Improvement, PGA, and individual symptom improvement) and final health outcomes (mortality, HRQoL e. Two independent investigators assessed studies for inclusion in a parallel manner based on a priori defined criteria in two-step processes. 2Department of Dermatology, Marchesi Hospital, Inzago, Milan, Italy3Dermatology and Venereology Private Practice, Bari and Barletta, Italy.

What are effective topical treatments for chronic plaque psoriasis? Learn more about psoriasis and why the immune system causes psoriasis to appear on the skin. When biopsied, psoriasis skin looks thicker and inflamed when compared to skin with eczema. It can also be very severe with thick, crusted plaques covering the entire scalp. However, only 2 to 3 percent of the population develops the disease. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. Patients who had both moderate to severe plaque psoriasis and psoriatic arthritis were enrolled from 98 international sites into this randomised multicentre study.

Cochrane For Clinicians: Topical Treatments For Chronic Plaque Psoriasis

Comparison of two treatments for chronic plaque psoriasis 3Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events A Meta-analysis of Randomized Controlled Trials. FIXTURE compared two doses of secukinumab (300 mg and 150 mg) with Enbrel 50 mg and placebo1. Topical treatments for chronic plaque psoriasis. Data from 2 identical phase-III studies, Oral-treatment Psoriasis Trial Pivotal 1 and 2, were pooled with data from these patients in an ongoing open-label long-term extension study. Clinical disease control for moderate to severe chronic plaque psoriasis typically requires continuous, long-term treatment. Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin. Psoriasis vulgaris (also known as chronic stationary psoriasis or plaque-like psoriasis) is the most common form and affects 85 90 of people with psoriasis. Two drugs that target T cells are efalizumab and alefacept. 86 88 Individuals with psoriasis or psoriatic arthritis have a slightly higher risk of heart disease and heart attacks when compared to the general population. To provide both ingredients in a two-compound product, efforts have been made to unite calcipotriol and betamethasone because they are usually inactivated when present in the same formulation. Background: One of the advances in the treatment of plaque-type psoriasis is combined local therapy with calcipotriol and betamethasone. The Cochrane Review of topical treatments for chronic plaque psoriasis3 analyzed the results of 2,058 patients from among five parallel-group studies to find proof of the efficacy of the two-compound product versus placebo in reduction of Psoriasis Area and Severity Index (PASI) score. Calcipotriol/betamethasone products were also compared to corticosteroids. The assessment found that the general efficacy of adalimumab, alefacept, etanercept, infliximab, and ustekinumab for the treatment of moderate to severe plaque psoriasis was supported by multiple good to fair randomized controlled trials.

Cochrane For Clinicians: Topical Treatments For Chronic Plaque Psoriasis

(etanercept) in the treatment of moderate to severe plaque psoriasis showed a significantly higher clinical response. The first-of-its-kind head-to-head study comparing two biologic agents for plaque psoriasis also shows the efficacy of STELARA among patients in the study who failed to respond to etanercept. Patients with moderate to severe psoriasis were randomized in a 2:1 ratio to adalimumab 80 mg (two 40 mg injections administered subcutaneously at baseline followed by one 40 mg injection every other week from Week 1 to Week 15) or placebo. Compared with the general US population, MCS scores at Week 16 were similar for patients receiving adalimumab (51. Baseline demographic and clinical characteristics were similar between the two treatment groups and were indicative of moderate to severe plaque psoriasis (Table 1). Little is known about the effect of specific anti interleukin-23 therapy, as compared with established anti tumor necrosis factor therapies, for the treatment of moderate-to-severe plaque psoriasis.